BNT142

BIOLOGICAL2 trials

Sponsors

BioNTech SE

Conditions

Solid TumorSolid Tumors

Phase 1

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

TerminatedNCT05262530

BioNTech SESolid Tumor

Start: 2022-03-22End: 2025-12-22Updated: 2026-04-08

First-in-human, open-label, multicenter, Phase I/IIa, dose-escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with CLDN6-positive advanced solid tumors

CompletedCTIS2024-512639-58-00

BioNTech SESolid Tumors

Start: 2022-05-07End: 2025-12-03Target: 119Updated: 2025-06-17

Related Papers

First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors.

Journal of Clinical Oncology2025-05-282 citations

Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6

Science Translational Medicine2024-05-2243 citations

The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis

Journal of Translational Medicine2023-08-1722 citations

A phase I/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors.

Journal of Clinical Oncology2023-06-0111 citations